Health TrialsbyHealthPanel

Impact of ICCAN on Cancer Treatment Completion and Quality of Life

ConditionCancer Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age21-80
SponsorMemorial Sloan Kettering Cancer Center

About this trial

The purpose of this study is to see if the ICCAN program is working, and to compare the ICCAN program to the standard hospital services provided in New York City hospitals, like meeting with a Social Worker or a Patient Navigator (a person who provides personal hospital guidance).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

fluent in English, Spanish, or Mandarin

between the ages of 21-80 years old

cancer patients currently receiving chemotherapy (started within the past month) and/or radiation therapy (started within the past week), or

scheduled to begin chemotherapy and/or radiation therapy within the next 2 months (excluding surgery only patients)

Disqualifiers

Diagnosed with Stage IV disease

Presence of untreated psychiatric disturbance (i.e. acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) verified by medical record sufficient to preclude completion of the assessment measures, interview or informed consent

Has another family member already enrolled in ICCAN (as determined by patient report)

Presence of untreated psychiatric disturbance (e.g., acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) sufficient to preclude completion of the assessment measures, interview or informed consent

Trial population

Eligible cancer patients will be recruited in person by multilingual ICCAN Clinical Research Coordinators for participation in the study at Ralph Lauren Center for Cancer Care and Prevention (RLCCP), Lincoln Hospital (LH) and Lutheran Medical Center (LMC). In the event that MSK staff is not present when an eligible patient is identified. Refinement and Pilot RCT participants will be recruited through MSK Manhattan and OneMSK regional sites's.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • The Integrated Cancer Care Access Network (ICCAN)

    Behavioral

    Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year. Chart review at 3 mo, 6 mo and 1 year, and as needed. Plus Initial needs assessment. Assistance with high priority social and economic needs.Monthly follow-up with ICCAN Access Facilitator to address ongoing needs in addition to as-needed assistance.

  • Usual and Customary Group (U&C)

    Behavioral

    Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year. Chart review at 3 mo, 6 mo and 1 year, and as needed.

Treatment groups

347 Participants
are divided into 3 treatment groups
Group A: Phase I: Refinement1 intervention
Group B: Phase II, Arm 1: Usual and Customary Care (U&C)1 intervention
Group C: Phase II, Arm 2: ICCAN-IO1 intervention

Trial outcomes

Primary outcomes

1

Treatment completion/adherence

The primary outcome, cancer treatment completion, will be determined by chart review at 3, 6, and 12 months after enrollment.

Time frame
1 year

Secondary outcomes

1

Quality of life

depression, and stress (measured through validated scales included in the Cancer Treatment Outcomes

Time frame
1 year

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Memorial Sloan Kettering Cancer Center

Lead sponsor

National Cancer Institute (NCI)

Collaborator

The City College of New York

Collaborator

Ralph Lauren Center for Cancer Care and Prevention

Collaborator

Lincoln Medical and Mental Health Center

Collaborator

Lutheran Medical Center

Collaborator

Source ClinicalTrials.gov
Apply now